GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Dolby Laboratories Inc (NYSE:DLB) » Definitions » Change In Receivables

Dolby Laboratories (Dolby Laboratories) Change In Receivables : $69 Mil (TTM As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Dolby Laboratories Change In Receivables?

Dolby Laboratories's change in receivables for the quarter that ended in Dec. 2023 was $-64 Mil. It means Dolby Laboratories's Accounts Receivable increased by $64 Mil from Sep. 2023 to Dec. 2023 .

Dolby Laboratories's change in receivables for the fiscal year that ended in Sep. 2023 was $48 Mil. It means Dolby Laboratories's Accounts Receivable declined by $48 Mil from Sep. 2022 to Sep. 2023 .

Dolby Laboratories's Accounts Receivable for the quarter that ended in Dec. 2023 was $293 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Dolby Laboratories's Days Sales Outstanding for the three months ended in Dec. 2023 was 84.79.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Dolby Laboratories's liquidation value for the three months ended in Dec. 2023 was $463 Mil.


Dolby Laboratories Change In Receivables Historical Data

The historical data trend for Dolby Laboratories's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dolby Laboratories Change In Receivables Chart

Dolby Laboratories Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57.20 35.55 -70.19 -8.01 48.13

Dolby Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.00 -51.94 170.37 14.69 -64.34

Dolby Laboratories Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dolby Laboratories  (NYSE:DLB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Dolby Laboratories's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=293.228/315.574*91
=84.79

2. In Ben Graham's calculation of liquidation value, Dolby Laboratories's accounts receivable are only considered to be worth 75% of book value:

Dolby Laboratories's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=797.639-573.219+0.75 * 293.228+0.5 * 37.568
=463

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dolby Laboratories Change In Receivables Related Terms

Thank you for viewing the detailed overview of Dolby Laboratories's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Dolby Laboratories (Dolby Laboratories) Business Description

Traded in Other Exchanges
Address
1275 Market Street, San Francisco, CA, USA, 94103-1410
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Executives
Kevin J Yeaman officer: VP, Chief Financial Officer C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
Mark Andrew Sherman officer: EVP, GEN. COUN. & SECRTY DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
John D Couling officer: SVP, Entertainment C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
Todd Pendleton officer: SVP, Chief Marketing Officer 1275 MARKET STREET, SAN FRANCISCO CA 94103
Emily Rollins director C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
Anjali Sud director C/O VIMEO INC., 555 WEST 18TH STREET, NEW YORK NY 10011
Simon Segars director C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
Avadis Tevanian director DOLBY LABORATORIES INC, 1275 MARKET STREET, SAN FRANCISCO CA 94103
Peter C Gotcher director
Ryan Nicholson officer: VP, Corporate Controller C/O DOLBY LABORATORIES INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
Shriram Revankar officer: SVP, Advanced Technology Group C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
Tony A Prophet director 9 BERNICE STREET, SAN FRANCISCO CA 94103
Robert J Park officer: SVP & Chief Financial Officer C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103
Steven E Forshay officer: Sr. Vice President, Research 1275 MARKET STREET, SAN FRANCISCO CA 94103
Lewis Chew officer: EVP, Chief Financial Officer DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO CA 94103